Deutsche Bank Ag\ Celyad Oncology Sa Transaction History

Deutsche Bank Ag\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$7.07 - $12.46 $3,535 - $6,230	-500 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$4.18 - $12.42 $4,915 - $14,605	-1,176 Reduced 70.17%	500 $4,000
Q4 2019 Feb 14, 2020	BUY	$8.46 - $12.74 $14,178 - $21,352	1,676 New	1,676 $17,000
Q3 2019 Nov 14, 2019	SELL	$9.6 - $14.88 $27,840 - $43,152	-2,900 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.94 - $22.64 $31,726 - $65,656	2,900 New	2,900 $33,000
Q4 2018 Feb 14, 2019	SELL	$16.0 - $28.17 $93,344 - $164,343	-5,834 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$26.49 - $31.86 $7,284 - $8,761	-275 Reduced 4.5%	5,834 $154,000
Q2 2018 Aug 14, 2018	BUY	$26.05 - $35.15 $27,560 - $37,188	1,058 Added 20.95%	6,109 $181,000
Q1 2018 May 15, 2018	BUY	$34.1 - $47.52 $52,889 - $73,703	1,551 Added 44.31%	5,051 $173,000
Q4 2017 Feb 14, 2018	BUY	$35.81 - $64.0 $125,335 - $224,000	3,500	3,500 $150,000

Ticker CYAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,594,000
Market Cap $11.7M
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.